Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) just unveiled an update.
On October 17, 2025, Palisade Bio, Inc. held its annual meeting of stockholders. During the meeting, three directors were elected, Baker Tilly US, LLP was ratified as the independent registered public accounting firm, and an amendment for a reverse stock split was approved. The reverse stock split, to be executed at a ratio between 1-for-5 and 1-for-50, is set to occur by December 31, 2025, at the board’s discretion.
The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Average Trading Volume: 7,926,405
Technical Sentiment Signal: Sell
Current Market Cap: $212.9M
For a thorough assessment of PALI stock, go to TipRanks’ Stock Analysis page.